SG Americas Securities LLC Has $3.32 Million Position in Tempus AI, Inc. $TEM

SG Americas Securities LLC grew its stake in Tempus AI, Inc. (NASDAQ:TEM) by 202.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,205 shares of the company’s stock after purchasing an additional 34,926 shares during the quarter. SG Americas Securities LLC’s holdings in Tempus AI were worth $3,317,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Concord Wealth Partners raised its holdings in Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after acquiring an additional 308 shares during the period. Allworth Financial LP boosted its holdings in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the period. SouthState Corp grew its position in shares of Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after purchasing an additional 489 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Tempus AI during the first quarter worth approximately $33,000. Finally, Creative Financial Designs Inc. ADV acquired a new stake in Tempus AI during the 2nd quarter worth approximately $47,000. Institutional investors own 24.22% of the company’s stock.

Insider Activity

In other news, Director David R. Epstein sold 370 shares of Tempus AI stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $90.00, for a total transaction of $33,300.00. Following the transaction, the director owned 26,671 shares in the company, valued at approximately $2,400,390. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the business’s stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the completion of the sale, the chief executive officer directly owned 9,141,032 shares in the company, valued at approximately $699,837,409.92. This represents a 3.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 1,007,870 shares of company stock valued at $80,663,575. Insiders own 26.27% of the company’s stock.

Tempus AI Price Performance

Tempus AI stock opened at $66.77 on Wednesday. The stock has a 50-day moving average price of $84.60 and a two-hundred day moving average price of $71.93. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The company has a market capitalization of $11.88 billion, a PE ratio of -56.11 and a beta of 4.86. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. The firm’s revenue was up 84.7% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. Analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEM. Morgan Stanley upped their price objective on Tempus AI from $68.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Guggenheim raised their price target on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, September 26th. Piper Sandler dropped their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Canaccord Genuity Group decreased their target price on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $80.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.